High-flow nasal cannula support therapy: new insights and improving performance
1Department of Critical Care Medicine, Virgen de la Salud University Hospital, Ave de Berber, 45005 Toledo, Spain
2Department of Critical Care Medicine, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
3Instituto de Salud Carlos III, Ciber Enfermedades Respiratorias (Ciberes), Madrid, Spain
1Department of Critical Care Medicine, Virgen de la Salud University Hospital, Ave de Berber, 45005 Toledo, Spain
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2017. Other selected articles can be found online at http://ccforum.com/series/annualupdate2017. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901.
Oxygen therapy is the first step in the prevention and treatment of hypoxemic respiratory failure and has traditionally been delivered using nasal prongs or masks. However, the maximal flow rates that these devices can deliver are limited because of the discomfort generated secondary to insufficient heat and humidity provided to the gas administered. Although high‐flow oxygen therapy is currently defined as flows greater than 30 l/min, it is accepted that flows up to 15 l/min can be delivered using conventional nasal prongs or masks; this flow is far less than the peak inspiratory flow of a patient with dyspnea. In addition, flows exceeding 6 l/min can lead to insufficient humidification provided to the nasal mucosa, even when a cold bubble humidifier is used. Therefore, room air dilutes the supplemental oxygen, resulting in a significant decrease in the fraction of the inspired oxygen (FiO2) that finally reaches the alveoli.
In recent years, new devices that deliver totally conditioned gas (37 °C containing 44 mg H2O/l [100% relative humidity] using a heated humidifier and a heated inspiratory circuit) through a wide bore nasal cannula at very high flow (up to 60 l/min) at a predetermined constant oxygen concentration (21 to 100%) have emerged as a safe and useful supportive therapy in many clinical situations.
High‐flow nasal cannula (HFNC) supportive therapy exerts its potential benefits through a variety of mechanisms. In the literature this treatment strategy has been variously described as nasal high flow and high flow oxygen therapy, but we believe that the most appropriate term is heated and humidified HFNC supportive therapy. This term reflects the features that generate the technique’s clinical effects (i. e., the delivery of warm and humidified air at high flows through a nasal cannula).
Physiological effects and consequences
Heated and humidified oxygen
Inhaling dry and cold oxygen provokes upper airway dryness frequently leading to intolerance, and potentially impairing mucociliary functions, such as secretion clearance and airway defense. Results of studies demonstrate that HFNC reduces patient discomfort and upper airway dryness, although a potentially protective effect on mucociliary function requires further investigation. Another way in which HFNC improves extubation outcome and weaning is by conditioning the inspired gas. Various studies have demonstrated that HFNC improves the management of respiratory secretions and reported fewer reintubations secondary to upper airway obstruction and accelerated weaning in tracheostomy patients. These findings support the idea that gas conditioning probably alleviates inflammation of the tracheal mucosa after transglottic intubation, and a protocol that includes the use of HFNC prior to extubation, thereby preventing the administration of dry and cold air in the native airway of the patients, reinforces this approach .
Carbon dioxide clearance
There is still not much information about the role of HFNC in managing hypercapnia, except for the mechanism of dead‐space washout. By providing a high flow of fresh air during expiration, HFNC may be able to more rapidly washout the carbon dioxide (CO2) filling the nasopharyngeal cavity. Möller et al. constructed an airway model using a computed tomography (CT) scan, and analyzed the lavage of gas tracers under apneic conditions. The authors observed a linear positive correlation between tracer‐gas clearance in the model and the flow rate of HFNC, approximately 1.8 ml/s increase in clearance for every 1.0 l/min increase in flow .
However, in recent years, new studies have highlighted some additional mechanisms affecting CO2 clearance. Alveolar ventilation has been suggested by Patel et al., after obtaining a mean apnea time of 17 min in surgical patients . The authors reported further evidence that classical apneic oxygenation provided little clearance of CO2 apart from that obtained from limiting rebreathing. Continuous insufflation of a high‐flow gas mixture facilitates oxygenation and CO2 clearance through gaseous mixing. Evidence for the existence of flow‐dependent, non‐rhythmic ventilatory exchange can be provided by comparing the increase in rise of CO2 under different continuous insufflation apneic conditions. While Rudolf and Hohenhorst  reported a rate of carbon dioxide increase of 0.24 kPa/min using a low‐flow oxygen intratracheal cannula (0.5 l/min), Patel et al.  achieved a rate of carbon dioxide increase of 0.15 kPa/min and a steady‐state carbon dioxide level was not reached. This result was improved only when using a high‐flow oxygen intratracheal cannula (45 l/min), reaching a steady‐state carbon dioxide level within 5 min of the start of the apnea .
Recently, Hernandez et al.  reported data supporting a possible role of HFNC in managing hypercapnia after extubation. The investigators compared non‐invasive ventilation (NIV) to HFNC in a fixed 24 h protocol after extubation in high‐risk for reintubation patients, using a non‐inferiority randomized trial. There was a trend towards a higher rates of postextubation respiratory failure due to hypercapnia in the NIV group than in the HFNC group, although this difference was not translated to the rates of hypercapnia as the reason for reintubation. They argued that the real time under NIV, clearly inferior to the 24 h expected by protocol, suggests that discomfort could have been the reason for hypercapnic postextubation respiratory failure in some NIV patients, as PaCO2 improved without any respiratory support in most patients. The reported rates of reintubation due to hypercapnia were similar in the two groups, as were the values of gasometric variables at reintubation, suggesting that high‐flow is at least as good as NIV for managing postextubation hypercapnia in high‐risk patients.
Positive pharyngeal pressure
HFNC can induce a positive pharyngeal pressure during expiration due to its constant ingoing flow, with the effect mainly determined by the flow rate provided by HFNC and the expiratory flow exhaled by the patient, with lower pressures when the patient keeps the mouth open.
Parke and McGuinness  reported that HFNC increased the mean pharyngeal pressure by about 1 cmH2O per 10 l/min, within a range of 30–50 l/min, but more recently , the same group reported that the linear increase in the pharyngeal pressure was maintained when using extra high‐flow with 100 l/min (combining two HFNC systems), obtaining pharyngeal pressures up to 11.9 cmH2O. However, these values were obtained in healthy volunteers and extrapolation to the critical care arena may not be accurate.
Despite this uncertainty about how much positive end‐expiratory pressure (PEEP) can really be offered by HFNC, studies  have demonstrated that end‐expiratory lung impedance increases with rising flow rate of HFNC, suggesting an increase in end‐expiratory lung volume. In addition, hemodynamic changes similar to those obtained in patients under NIV with pressure levels close to 10 cmH2O have been reported . Right atrial pressure has been considered as a surrogate of right ventricular preload and is most commonly estimated by inferior vena cava (IVC) diameter and the presence of inspiratory collapse. Changes in IVC diameter have been used to determine preload responsiveness in positive pressure ventilated patients. In a population of patients with New York Heart Association (NYHA) class III heart failure, treatment with HFNC at 20 and 40 l/min was associated with mean attributable reductions in the IVC inspiratory collapse of 20 and 53% from baseline, respectively. These changes were reversible after HFNC withdrawal suggesting that HFNC therapy may modify the hemodynamic status in heart failure patients at the same rate as does NIV.
HFNC is, therefore, not entirely similar to applying continuous positive airway pressure (CPAP), which aims to maintain a steady level of positive pressure during the whole cycle of breath. The target of HFNC is flow instead of pressure, so the objective when applying HFNC should not be the pharyngeal pressure measured but the changes in hemodynamic status and the increase in lung aeration.
Acute hypoxemic respiratory failure
Effects of HFNC on physiological variables and comfort
The first studies in patients with acute respiratory failure focused on the effects of HFNC therapy on physiological variables [10–12] and reported oxygenation enhancement with reductions in respiratory rate and no changes in PaCO2 (Table 1). Moreover, HFNC appeared to be better tolerated and achieved a greater level of comfort than conventional oxygen devices [10, 12]. HFNC was also usually better tolerated than NIV, although NIV obtained greater improvements in oxygenation [13, 14].
|Condition||Author [ref]||Design||Patients||Main results|
|Acute respiratory failure (ARF)||Roca et al. ||Retrospective cohort||37 lung transplant recipients readmitted to ICU due to ARF (40 episodes)||The absolute risk reduction for MV with HFNC was 29.8%, and the NNT to prevent one intubation with HFNC was 3. Multivariate analysis showed that HFNC therapy was the only variable at ICU admission associated with a decreased risk of MV (OR 0.11 [95% CI 0.02–0.69]; p = 0.02)|
|Frat et al. ||Randomized controlled trial||313 ARF patients randomly assigned to HFNC, conventional oxygen therapy or NIV||The hazard ratio for death at 90 days was 2.01 (95% CI 1.01 to 3.99) with conventional oxygen therapy vs HFNC (p = 0.046) and 2.50 (95% CI, 1.31 to 4.78) with NIV vs HFNC (p = 0.006). In the subgroup of patients with a PaO2/FiO2 ≤ 200 mmHg, the intubation rate was significantly lower in the HFNC group|
|Rello et al. ||Retrospective cohort||35 patients with ARF due to H1N1 viral pneumonia||After 6 h of HFNC, non‐responders had a lower PaO2/FiO2. All 8 patients on vasopressors required intubation|
|Lemiale et al. ||Randomized controlled trial||100 immunocompromised patients with ARF randomized to a 2 h of HFNC vs conventional oxygen||No differences in NIV or invasive MV during the 2 h period were observed.
No differences in secondary outcomes (RR, HR, comfort, dyspnea and thirst) were observed
|Mokart et al. ||Retrospective propensity‐score analysis||178 cancer patients admitted to the ICU due to severe ARF||HFNC‐NIV was associated with more VFD and less septic shock occurrence.
Mortality of patients treated with HFNC 35 vs 57% for patients never treated with HFNC, p = 0.008
|Kang et al. ||Retrospective cohort||175 patients who failed on HFNC and required intubation||In propensity‐adjusted and ‐matched analysis, early intubation (<48 h) was associated with better overall ICU mortality [adjusted OR = 0.317, p = 0.005; matched OR = 0.369, p = 0.046]|
|Frat et al. ||Post‐hoc analysis of a randomized controlled trial||82 immunocompromised patients of the FLORALI study||NIV was associated with higher risk of intubation and mortality|
|Roca et al. ||Prospective cohort||157 patients with severe pneumonia||ROX index, defined as ratio of SpO2/FiO2 to respiratory rate, ≥ 4.88 measured after 12 h of HFNC was significantly associated with lower risk for MV (HR 0.273 [95% CI 0.121–0.618])|
|Coudroy et al. ||Retrospective cohort||115 immunocompromised patients||The rates of intubation and 28‐day mortality were significantly higher in patients treated with NIV than with HFNC|
|Cardiac surgery||Parke et al. ||Randomized||60 patients with non‐severe hypoxemic ARF were randomized to receive HFNC or oxygen therapy||HFNC patients tended to need NIV less frequently (10 vs 30%; p = 0.10) and had significantly fewer desaturations (p = 0.009)|
|Parke et al. ||Randomized controlled trial||340 patients after cardiac surgery randomized to HFNC vs conventional oxygen therapy for 48 h||No differences in oxygenation on Day 3 after surgery were observed, but HFNC did reduce the requirement for escalation of respiratory support (OR 0.47, 95% CI 0.29–0.7, p = 0.001)|
|Corley et al. ||Randomized controlled trial||155 extubated patients with BMI ≥ 30 kg/m2 received conventional oxygen therapy or HFNC||No difference was seen between groups in atelectasis. There was no difference in mean PaO2/FiO2 ratio or RR. Five patients failed allocated treatment in the control group compared with three in the treatment group (OR 0.53; 95% CI 0.11, 2.24, p = 0.40)|
|Stephan et al. ||Randomized noninferiority trial||830 cardiothoracic surgical patients who developed ARF or were deemed at risk for respiratory failure after extubation. HFNC vs BiPAP||The treatment failed in 87 (21.0%) of 414 patients with HFNC and 91 (21.9%) of 416 patients with BiPAP (p = 0.003). No significant differences were found for ICU mortality (23 patients with BiPAP [5.5%] and 28 with HFNC [6.8%]; p = 0.66)|
|Pre‐intubation||Vourc’h et al. ||Randomized controlled trial||124 patients with PaO2/FIO2 ratio < 300 mmHg, RR ≥ 30 bpm and FIO2 ≥ 0.5. Randomized to HFNC or facial mask||No differences in the lowest saturation was observed (HFNC 91.5% vs high flow facial mask 89.5%; p = 0.44). There was no difference in difficult intubation, VFD, intubation‐related adverse events including desaturation < 80% or mortality|
|Post‐extubation||Maggiore et al. ||Randomized controlled trial||105 patients with PaO2/FiO2 ≤ 300 before extubation who were randomized to 48 h of conventional oxygen therapy or HFNC||HFNV improved the PaO2/FiO2 ratio, comfort, airway dryness, episodes of interface displacements, oxygen desaturations, reintubation rate, or any form of ventilator support|
|Rittayamai et al. ||Randomized crossover study||17 patients were randomized after extubation to sequential HFNC and conventional oxygen therapy for 30 min periods||At the end of the study, patients with HFNC reported less dyspnea and lower RR and HR. Most of the subjects (88.2%) preferred HFNC to conventional oxygen therapy|
|Tiruvoipati et al. ||Randomized crossover study||50 patients were randomized to sequential HFNC and facial mask after extubation||There was no significant difference in gas exchange, RR or hemodynamics. HFNC was better tolerated (p = 0.01) and tended to be more comfortable (p = 0.09)|
|Hernandez et al. ||Randomized controlled trial||527 extubated patients without any high‐risk factor for reintubation were randomized to either HFNC or conventional oxygen therapy for 24 h||Reintubation within 72 h was less common in the high‐flow group, 4.9 vs 12.2% in the conventional group (p = 0.004). Postextubation respiratory failure was less common in the high‐flow group 8.3 vs 14.4% in the conventional group (p = 0.03)|
|Hernandez et al. ||Randomized non‐inferiority trial||604 extubated patients with at least one high‐risk factor for reintubation were randomized to either HFNC or NIV for 24 h||Reintubation within 72 h was noninferior in the HFNC group compared to the NIV group (22.8 vs 19.1%, absolute difference, −3.7%; 95% CI −9.1% to ∞); postextubation respiratory failure was lower in the HFNC group (26.9 vs 39.8%, risk difference, 12.9%; 95% CI 6.6% to ∞)|
|Invasive procedures||Lucangelo et al. ||Randomized controlled trial||45 patients were randomly assigned to 3 groups: Venturi mask, nasal cannula, and HFNC during bronchoscopy||At the end of bronchoscopy, HFNC‐treated patients had higher PaO2/FiO2, and SpO2|
|Simon et al. ||Randomized controlled trial||40 patients with hypoxemic ARF received NIV or HFNC during bronchoscopy||NIV group had better oxygenation. Two patients with HFNC were unable to proceed to bronchoscopy due to progressive hypoxemia|
|Heart failure||Roca et al. ||Prospective cohort||10 adult patients with NYHA class III and left ventriclar ejection fraction 45% or less||Median inspiratory IVC collapse significantly (p < 0.05) decreased from baseline (37%) to HFNC with 20 l/min (28%) and HFNC with 40 l/min (21%). Changes in IVC inspiratory collapse were reversible|
|Emergency department||Rittayamai et al. ||Randomized comparative study||40 hypoxemic patients were randomized to receive HFNC or conventional oxygen for 1 h||HFNC improved dyspnea and comfort.
No serious adverse events related to HFNC were observed
|Jones et al. ||Randomized controlled trial||303 hypoxemic and tachypneic patients admitted to the lemergency department||5.5% of HFNC patients vs 11.6% of conventional oxygen therapy patients required MV within 24 h of admission (p = 0.053)|
MV mechanical ventilation, RR respiratory rate, ICU intensive care unit, ARF acute respiratory failure, VFD ventilator‐free days, NNT number needed to treat, COT conventional oxygen therapy, NIV non‐invasive ventilation, HR heart rate, BMI body mass index, IVC inferior vena cava
In addition, HFNC has been used in small cohorts of patients with acute respiratory failure in the emergency department [15, 16] and even in 150 children less than 2 years old during interhospital transport . The effects on oxygenation and rates of intubation reported in all these studies are similar to those found when HFNC has been used in patients with acute respiratory failure admitted to critical care areas, suggesting that, with adequate monitoring, HFNC can be safely used outside the critical care setting.
Effects on intubation rate and mortality
These physiological studies provide the rationale for considering HFNC as a potentially useful tool for decreasing intubation rates and mortality in patients with acute respiratory failure. The first randomized controlled trial (RCT) included postoperative cardiac surgery patients with mild to moderate acute respiratory failure . In that preliminary trial, HFNC patients were less likely to need escalation to NIV and had fewer desaturations than those treated using a standard humidified high flow face mask. In another retrospective analysis of a prospectively assessed cohort of 37 lung transplant patients readmitted to the ICU because of acute respiratory failure, HFNC therapy was the only variable at ICU admission associated with a decreased risk of mechanical ventilation in the multivariate analysis . The absolute risk reduction for mechanical ventilation with HFNC was 29.8%, and only three patients needed to be treated with HFNC to prevent one intubation. Moreover, non‐ventilated patients had an increased survival rate.
More recently, the results of the first large RCT to assess clinical outcomes with HFNC (50 l/min), conventional oxygen devices and NIV have been published . The study included 310 patients with de novo hypoxemic acute respiratory failure, defined as PaO2/FiO2 ratio ≤ 300 mmHg or respiratory rate > 25 bpm with 10 lpm of O2. Patients with a history of chronic respiratory disease, including chronic obstructive pulmonary disease (COPD), as well as patients with acute cardiogenic pulmonary edema, severe neutropenia and hypercapnia (PaCO2 > 45 mmHg) were excluded, as were patients with other organ failures, including hemodynamic instability or vasopressors at the time of inclusion. The most frequent cause of acute respiratory failure was pneumonia (75%) and 80% of the enrolled patients showed bilateral pulmonary infiltrates at study inclusion. The primary outcome (the rate of endotracheal intubation) did not differ significantly between the groups (HFNC 38% vs. standard oxygen 47% and NIV 50%; p = 0.18).
This negative result may be due to the fact that the observed rate of intubation with standard oxygen was lower than expected and, therefore, the study may have been underpowered. However, a post hoc adjusted analysis including the 238 patients with a PaO2/FiO2 ratio ≤ 200 mmHg found that HFNC reduced intubation rates (p = 0.009). In the entire cohort, HFNC increased ventilator‐free days, reduced 90‐day mortality and was associated with better comfort and lower dyspnea severity. In contrast, NIV patients had higher 90‐day mortality rates than HFNC patients.
Mechanisms that may explain these findings are the small amount of positive airway pressure and increased CO2 excretion with HFNC, the overall reduction in the need for intubation and the lower incidence of septic shock. Moreover, important concerns have been raised regarding how NIV was applied. First, half of the patients in the NIV group were treated with NIV for less than eight hours during the first two days of randomization and received HFNC between NIV sessions. Second, high tidal volumes (9.2 ± 3.0 ml/kg) were used, which may have aggravated the preexisting lung injury. In fact, patients with acute respiratory failure usually have high respiratory rates and minute volumes and are more likely to present patient‐ventilator asynchronies. Third, relatively low levels of PEEP were used in potentially recruitable patients (5 ± 1 cmH2O). Fourth, intermittent sessions of NIV may induce the phenomenon of recruitment/derecruitment, generating ventilator‐induced lung injury (VILI). Finally, NIV was delivered through a face mask although it has later been shown that a helmet interface may be associated with better outcomes [21, 22]. Thus, the NIV protocol in this study could be assumed to be close to what is real practice at the bedside in many centers treating acute respiratory failure with NIV, so an underestimation of the NIV treatment effect in a pragmatic trial cannot be ruled out.
More recently, a post hoc subgroup analysis in a subset of immunocompromised patients was performed on the FLORALI study . Thirty patients treated with standard oxygen therapy, 26 treated with HFNC, and 26 treated with NIV were included. The intubation and mortality rates were significantly higher in patients randomly assigned to NIV and, apart from age, the use of NIV as the first‐line therapy was the only variable independently associated with a higher risk of endotracheal intubation and mortality in the multivariate logistic regression analysis. Moreover, the expired tidal volume measured 1 h after NIV initiation was higher in the patients who died than in survivors (11.1 ± 2.6 ml/kg of predicted weight versus 7.6 ± 3.1 ml/kg; p = 0.02). Similarly, higher tidal volumes have been associated with NIV failure .
Thus, the high tidal volumes and high transpulmonary pressures obtained during NIV may induce VILI in a pre‐injured lung and may be at least partially responsible for NIV failure and higher mortality. These results were similar to those observed in a recently published 8‐year observational study of a cohort of 115 immunocompromised patients .
Two recent systematic reviews and meta‐analyses have also been published that evaluated the effectiveness of HFNC [26, 27]. In the first study, no differences in terms of mortality or higher respiratory support requirement was observed . Most recently, Monro‐Somerville et al.  found that, although HFNC appears to be well tolerated, no difference in intubation rates or mortality was observed in patients treated with HFNC compared to those treated with usual care (conventional oxygen or NIV). However, the required information size was not reached: in fact, only 30.6 and 62.3% of the estimated needed patients were included for the primary (mortality) and secondary (intubation) outcomes, respectively. Moreover, HFNC was shown to have better survival and lower intubation rates than conventional oxygen and, although no differences were observed compared with NIV, HFNC was better tolerated. Finally, certain methodological issues regarding some of the studies included in both meta‐analyses should be noted. First, a study by Stephan et al.  was a positive non‐inferiority trial comparing HFNC and NIV; however, in the meta‐analysis it appears as a negative trial as no differences were observed between HFNC and NIV. Second, in a study by Lemiale et al. , HFNC was only used for a 2 h‐trial and in such a short period of time it would be difficult to observe any difference between treatments. Finally, and most importantly, studies included in both meta‐analyses had very heterogeneous populations of acute respiratory failure patients in terms of severity with huge differences in risks of intubation.
Predictors of HFNC success
The existence of accurate, early predictors of HFNC success is important. Indeed, a recent propensity‐score analysis associated early intubation (within the first 48 h) with better ICU survival . In spite of its limitations, the study by Kang et al.  raises an important issue – the fact that delayed intubation may worsen the prognosis of patients treated with HFNC. Therefore, the ability to describe accurate predictors of HFNC success that can allow timely endotracheal intubation in patients who are likely to fail is a point of special interest. Sztrymf et al.  reported that respiratory rate as well as the percentage of patients exhibiting thoraco‐abdominal asynchrony as early as 30 and 15 min after the beginning of HFNC were significantly higher in patients who required endotracheal intubation. Moreover, the PaO2/FiO2 ratio 1 h after the start of HFNC was significantly lower in patients requiring invasive mechanical ventilation. Similarly, in a series of 20 patients with H1N1 infection treated with HFNC, worse PaO2/FiO2 ratios were observed in patients who required intubation after six hours of treatment . Interestingly, a recent prospective study showed that patients with severe pneumonia who had a ROX index (defined as the ratio of SpO2/FiO2 to respiratory rate) ≥ 4.88 after 12 h of HFNC therapy were less likely to be intubated, even after adjusting for potential covariates . Moreover, among patients who were still on HFNC after 18 h, the median change in the ROX index between 18 and 12 h was significantly higher in patients who did not require intubation. However, non‐pulmonary severity has also been described as a good predictor of HFNC failure. Indeed, the presence of shock has been associated with a higher risk of mechanical ventilation [19, 23].
In a preliminary study by Hernandez et al.  titrating high‐flow according to patient tolerance, a gas flow > 35 l/min 12 h after extubation predicted reintubation, suggesting that the flow tolerated by patients is a marker of severity; unfortunately, this result was not reproduced in the subsequent randomized trial .
Another controversial issue is whether patients with bilateral infiltrates treated with HFNC can be considered as having acute respiratory distress syndrome (ARDS). In fact, most patients included in studies have bilateral infiltrates [20, 32]. The Berlin definition of ARDS  requires a minimum of 5 cmH2O of PEEP, and it has been shown that HFNC can provide a level of PEEP that is higher at peak expiratory pressure . Moreover, ARDS does not begin at the time of mechanical ventilation onset. Therefore, it can be accepted that patients with a risk factor for ARDS, who are hypoxemic (PaO2/FiO2 ratio ≤ 300 mmHg) and have bilateral infiltrates not fully explained by cardiac failure or fluid overload, may be considered as ARDS patients. In these patients, HFNC may achieve success rates similar to those of NIV .
Prevention of postextubation respiratory failure and reintubation
Extubation failure is an independent predictor of mortality. The development of therapies to prevent this has been focused on specific causes of reintubation (corticoids for larynx edema and NIV for hypercapnic respiratory failure in patients with chronic pulmonary diseases) and in patients with risk factors associated with extubation failure. Usually, extubated patients receive conventional oxygen therapy for correcting the oxygenation impairment. This system provides low flow and does not guarantee the FiO2.
Two preliminary physiological studies comparing HFNC with conventional oxygen devices using a crossover design and during a short period of time after extubation have confirmed the consistent benefit of HFNC in terms of overall comfort. Rittayamai et al.  observed a decrease in respiratory rate and heart rate when comparing HFNC therapy at 35 l/min vs conventional oxygen devices at 6–10 l/min in 17 patients during a 30 min period. In contrast, Tiruvoipati et al.  found no change in these physiological variables when comparing 30 l/min delivered through HFNC or 15 l/min through a high flow face mask. Shortly after this study, the first RCT comparing HFNC with conventional oxygen devices after extubation was published . The study included patients with acute respiratory failure due to pneumonia and trauma who were mechanically ventilated for a mean of almost five days before extubation. In these patients, the use of HFNC was associated with better comfort, better oxygenation, fewer desaturations and interface displacements, and a lower reintubation rate.
Postoperative patients remain an important subgroup of patients with some differences related to the response to HFNC. The effectiveness of HFNC therapy during the extubation period in postoperative patients remains controversial; most studies on this issue have included patients after cardiothoracic surgery. Parke et al.  included a non‐selected population of cardiac surgery patients with mild to moderate acute respiratory failure, observing that HFNC patients more frequently succeeded and could be weaned to conventional oxygen devices. In contrast, in patients randomized to conventional oxygen devices, acute respiratory failure was more likely to worsen and escalation to NIV or HFNC required. Corley et al.  included a population of cardiac surgery patients with body mass index (BMI) ≥ 30 who were randomly assigned to prophylactic HFNC therapy or conventional oxygen devices after extubation. The authors did not observe any difference in atelectasis formation, oxygenation, respiratory rate, or dyspnea. Finally, the BiPOP study , a multicenter, non‐inferiority RCT, compared HFNC and NIV for preventing or resolving acute respiratory failure after cardiothoracic surgery. Three different types of patient were eligible: patients who failed after a spontaneous breathing trial; patients who succeeded but had a preexisting risk factor for postoperative acute respiratory failure (BMI > 30, left ventricular ejection fraction < 40%, and failure of previous extubation); and patients who succeeded after a spontaneous breathing trial but then failed extubation (defined as at least one of the following: PaO2/FiO2 < 300, respiratory rate > 25 bpm for at least 2 h, and use of accessory respiratory muscles or paradoxical respiration). After randomizing more than 800 patients, HFNC therapy did not increase the rate of treatment failure (defined as reintubation, switch to the other study treatment, or premature treatment discontinuation at the patient’s request or due to an adverse event). Therefore, as HFNC therapy did not worsen outcomes, may be easier to administer, and requires lower nursing workload, the authors concluded that the results supported the use of HFNC in this subset of patients. Certain questions remain unanswered, however, such as the optimal flow and the subset of patients who would benefit the most from HFNC therapy.
Recently, Hernandez et al.  reported a multicenter randomized trial analyzing the effect of HFNC compared to conventional oxygen therapy in a population of low‐risk‐of‐reintubation patients. In the study, the authors aimed to evaluate whether high flow oxygen therapy after planned extubation would reduce the need for reintubation compared with standard oxygen therapy. The all‐cause reintubation within 72 h was lower in the high flow group (4.9 vs 12.2%). This difference was mainly attributable to a lower incidence of respiratory‐related reintubations in the high flow group (1.5% vs 8.7%). The main benefit was observed on reducing reintubation secondary to hypoxemia and inability to clear secretions. These results agree with those obtained by Maggiore et al. .
The authors classified patients according to the criteria for risk of reintubation. They did not use the type of respiratory failure considering that the aim was to obtain the preventive effects of HFNC and not treatment once the failure was present. It is currently unclear how to identify at risk patients for extubation failure. Previous trials, like that of Thille et al. , have tried to identify the underlying risks of extubation outcome. In keeping with these studies, this trial included 10 risk factors, which can clearly select a low risk population.
Simultaneously, Hernandez et al.  compared HFNC with NIV in patients at high risk for reintubation in a non‐inferiority trial. While studies have suggested that prophylactic NIV could prevent postextubation respiratory failure, they appear inconsistent with regard to reintubation. However, Thille et al.  added new data supporting the benefit of NIV for this indication. In a general population of critical patients use of NIV has not been proved, for that reason in the low‐risk group HFNC was compared to conventional oxygen therapy .
This study confirmed that the reintubation rate was non‐inferior in the HFNC group compared to the NIV group within 72 h (22.8% vs 19.1%). For postextubation respiratory failure, the authors reported a lower rate in the HFNC group compared to the NIV group (26.9% vs 39.8%), suggesting that the postextubation respiratory failure rate could be even higher in the NIV group. This surprising result was explained by the significantly higher adverse event rate in the NIV group (43% vs 0%), mainly discomfort and subsequent early withdrawal of the therapy (mean real time under NIV 14 h, instead of the 24 h per protocol). This increased postextubation respiratory failure rate was not correlated with the reintubation rate, supporting a possible role of discomfort in NIV patients as the reason for the postextubation respiratory failure. In addition, the length of hospital stay was significantly reduced in the HFNC group .
Facilitating weaning in tracheostomized patients
Weaning of tracheostomy patients is still a challenge. To our knowledge, only one randomized trial has included high flow therapy in the protocol . This was a single‐center study including 181 critically ill tracheostomy patients who were randomized to have the tracheal cuff deflated or not during spontaneous breathing trials. All patients received high‐flow conditioned oxygen therapy through a direct tracheostomy connection to the maximum tolerated flow and conditioned up to 37 °C. Although that study was not specifically designed to assess the effectiveness of high flow through the trachea, the authors hypothesized that HFNC therapy may have some benefits in the weaning process of tracheostomy patients with a deflated tracheal cuff. Positive airway pressure may theoretically reduce microaspiration and, with a deflated cuff, a higher flow is conveyed through the pericannular space, allowing for better drainage of secretions.
Regarding the methodology used in the protocol by Hernandez et al. , HFNC was applied before extubation to prevent the entrance of dry and cold air into the patient’s native airway from the start of treatment. Although this is speculative, it could play a major role in the early benefit that was found in the lower rate of upper airway obstruction (laryngeal edema requiring reintubation was not observed in the HFNC group).
Flow was titrated according to patient tolerance; initially set at 10 l/min and titrated upward in 5 l/min steps until patients experienced discomfort. Twelve hours after extubation, a steady state is usually obtained. In that low‐risk‐of‐reintubation study, authors observed a tolerated main gas flow of 31 l/min, a moderate flow as compared to the main flow tolerated in the high‐risk‐of‐reintubation study (50 l/min), reinforcing the idea that under these conditions the flow tolerated is a marker of severity.
Another point of the protocol used by Hernandez et al.  deserves mention: patients who tolerated the spontaneous breathing trial were reconnected with the previous ventilator settings for rest and clinical evaluation of airway patency. Some preliminary studies suggest that spontaneous breathing trials could lead to mild respiratory muscle fatigue that could somehow influence extubation success. However, clinical evidence supporting this hypothesis is lacking.
After 24 h, high‐flow therapy was stopped and, if necessary, patients received conventional oxygen therapy. Maggiore et al.  reported better results using high‐flow for 48 h after extubation, with some of the variables showing significant improvement after 24 continuous hours of application, suggesting that some time‐dependent effects could lead to improved performance of this therapy.
With this information in mind, clinicians should counterbalance efficacy and safety. On the one hand, the longer the duration of HFNC application, the greater the clinical efficacy. On the other hand, the longer the duration of HFNC, the greater the probability of delaying escalation of respiratory support when HFNC fails. In fact, as suggested by Kang et al. , applying HFNC in patients with respiratory failure according to clinical response could lead to delayed intubation. This could be associated with a worse outcome, as has been shown with NIV. This may be possible because HFNC increases comfort, oxygenation and may disguise respiratory distress. The results by Hernandez et al. , reinforce this idea; under a fixed 24‐hour protocol after extubation, the time to reintubation was not increased, whether compared to conventional oxygen therapy in the low‐risk‐of‐reintubation group or NIV in the high‐risk‐of‐reintubation group. A 24‐h limit probably helped physicians appreciate undertreated respiratory distress at an early stage and not delay reintubation. Nevertheless, the results confirmed that 24 h was enough to reduce the rate of reintubation.
HFNC does not delay reintubation under those conditions. This result can be attributed to the preventive intention, the fixed duration and to the predefined reintubation criteria.
Delivery of heated and humidified oxygen at high flow rates through nasal cannulas is now widely used in adult patients. Its mechanisms of action and potential clinical benefits can help to improve the management of patients with acute respiratory failure or during the weaning phase. With the currently available evidence, several questions still remain unanswered; there is strong evidence for some clinical indications, but for other situations without that evidence decisions on HFNC treatment should be individualized in each particular situation and institution, taking into account resources, and local and personal experience with all respiratory support therapies. However, HFNC therapy is an innovative and powerful technique that is currently changing the management of patients with respiratory failure.
The authors highlight the contributions of the Spanish Multidisciplinary Group of High Flow Supportive therapy in adults (HiSpaFlow).
Publication charges were funded by Fisher&Paykel.
Availability of data and materials
All the authors made substantial contributions to the work and drafting or revising it critically for important intellectual content. All the authors gave their final approval to the version submitted for publication.
Fisher&Paykel support a post doctoral fellow in Medical Research at the Hospital del Mar Institute. OR and GH have travel expenses and GH has personal fees covered by Fisher&Paykel.
Consent for publication
Ethics approval and consent to participate
Gonzalo Hernández, Email: ten.acinofelet@mzednanrehg.
Oriol Roca, Email: firstname.lastname@example.org.
Laura Colinas, Email: moc.liamg@zednanrefsanilocarual.
Articles from Critical Care are provided here courtesy of BioMed Central